Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi Will Buy Brazilian Drugmaker

by Marc S. Reisch
April 13, 2009 | A version of this story appeared in Volume 87, Issue 15

Sanofi-Aventis has undertaken two deals to enlarge its generic drug portfolio and position in Latin America. In the first deal, the French pharmaceutical maker signed an agreement to acquire the Brazilian generic drugmaker Medley in a transaction valued at $665 million. Medley is the third-largest pharmaceutical company in Brazil, with $203 million in sales last year and 1,550 employees. Two-thirds of Medley's sales are in generics. Together with its existing operations and 2,300 employees in Brazil, the acquisition will give Sanofi-Aventis a 12% share of the Brazilian drug market, which is growing 20% annually. Separately, Sanofi-Aventis has acquired Laboratorios Kendrick, a Mexican generic drugmaker that had $35 million in sales last year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.